High-avidity CTL exploit two complementary mechanisms to provide better protection against viral infection than low-avidity CTL

被引:175
作者
Derby, MA [1 ]
Alexander-Miller, MA [1 ]
Tse, R [1 ]
Berzofsky, JA [1 ]
机构
[1] NCI, Mol Immunogenet & Vaccine Res Sect, Metab Branch, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.4049/jimmunol.166.3.1690
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Previously, we observed that high-avidity CTL are much more effective in vivo than low-avidity CTL in elimination of infected cells, but the mechanisms behind their superior activity remained unclear. In this study, we identify two complementary mechanisms: 1) high-avidity CTL lyse infected cells earlier in the course of a viral infection by recognizing lower Ag densities than those distinguished by low-avidity CTL and 2) they initiate lysis of target cells more rapidly at any given Ag density. Alternative mechanisms were excluded, including: 1) the possibility that low-avidity CTL might control virus given more time (virus levels remained as high at 6 days following transfer as at 3 days) and 2) that differences in efficacy might be correlated with homing ability. Furthermore, adoptive transfer of high- and low-avidity CTL into SCID mice demonstrated that transfer of a 10-fold greater amount of low-avidity CTC could only partially compensate for their decreased ability to eliminate infected cells. Thus, we conclude that high-avidity CTL exploit two complementary mechanisms that combine to prevent the spread of virus within the animal: earlier recognition of infected cells when little viral protein has been made and more rapid lysis of infected cells.
引用
收藏
页码:1690 / 1697
页数:8
相关论文
共 45 条
[31]   Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positiye relapsed Hodgkin's disease [J].
Roskrow, MA ;
Suzuki, N ;
Gan, YJ ;
Sixbey, JW ;
Ng, CYC ;
Kimbrough, S ;
Hudson, M ;
Brenner, MK ;
Heslop, HE ;
Rooney, CM .
BLOOD, 1998, 91 (08) :2925-2934
[32]  
Santin AD, 2000, EUR J GYNAECOL ONCOL, V21, P17
[33]   IN-VITRO PREDICTORS OF THERAPEUTIC RESPONSE IN MELANOMA PATIENTS RECEIVING TUMOR-INFILTRATING LYMPHOCYTES AND INTERLEUKIN-2 [J].
SCHWARTZENTRUBER, DJ ;
HOM, SS ;
DADMARZ, R ;
WHITE, DE ;
YANNELLI, JR ;
STEINBERG, SM ;
ROSENBERG, SA ;
TOPALIAN, SL .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (07) :1475-1483
[34]  
Soda H, 1999, J SURG ONCOL, V72, P211, DOI 10.1002/(SICI)1096-9098(199912)72:4<211::AID-JSO6>3.0.CO
[35]  
2-A
[36]   AN IMMUNODOMINANT EPITOPE OF THE HUMAN IMMUNODEFICIENCY VIRUS ENVELOPE GLYCOPROTEIN GP160 RECOGNIZED BY CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE-RESTRICTED MURINE CYTO-TOXIC LYMPHOCYTES-T [J].
TAKAHASHI, H ;
COHEN, J ;
HOSMALIN, A ;
CEASE, KB ;
HOUGHTEN, R ;
CORNETTE, JL ;
DELISI, C ;
MOSS, B ;
GERMAIN, RN ;
BERZOFSKY, JA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (09) :3105-3109
[37]  
TAKESHITA T, 1995, J IMMUNOL, V154, P1973
[38]   Rapid death of adoptively transferred T cells in acquired immunodeficiency syndrome [J].
Tan, RS ;
Xu, XN ;
Ogg, GS ;
Hansasuta, P ;
Dong, T ;
Rostron, T ;
Luzzi, G ;
Conlon, CP ;
Screaton, GR ;
McMichael, AJ ;
Rowland-Jones, S .
BLOOD, 1999, 93 (05) :1506-1510
[39]   Serial triggering of TCRs: A basis for the sensitivity and specificity of antigen recognition [J].
Valitutti, S ;
Lanzavecchia, A .
IMMUNOLOGY TODAY, 1997, 18 (06) :299-304
[40]   SERIAL TRIGGERING OF MANY T-CELL RECEPTORS BY A FEW PEPTIDE-MHC COMPLEXES [J].
VALITUTTI, S ;
MULLER, S ;
CELLA, M ;
PADOVAN, E ;
LANZAVECCHIA, A .
NATURE, 1995, 375 (6527) :148-151